Positions

Overview

  • Introduction:
    Graduate of Duke University undergraduate and Chapel Hill Medical School. Completed internship/residency at UAB followed by fellowship at UAB. Currently Professor of Medicine with a focused interest in education, clinical investigation in head and neck cancer and breast cancer, and quality metrics for patient care.

    Clinical Interests:

    Clinical investigation in head and neck cancer and breast cancer, and quality metrics for patient care.

    Research:

    Head and Neck Cancer, Breast Cancer, GU Cancer, and Sarcoma.

    • Selected Publications

    Academic Article

    Year Title Altmetric
    2023 Time to treatment initiation and its impact on real-world survival in metastatic colorectal cancer and pancreatic cancer.  Cancer Medicine.  12:3488-3498. 2023
    2023 Traditional risk factors and cancer-related factors associated with cardiovascular disease risk in head and neck cancer patients.  Frontiers in Cardiovascular Medicine.  9. 2023
    2022 Zanidatamab, a novel bispecific antibody, for the treatment of locally advanced or metastatic HER2-expressing or HER2-amplified cancers: a phase 1, dose-escalation and expansion study 2022
    2022 BETA PRIME: Phase I study of AdAPT-001 as monotherapy and combined with a checkpoint inhibitor in superficially accessible, treatment-refractory solid tumors.  Future Oncology.  18:3245-3254. 2022
    2022 Racial and rural–urban disparities in cardiovascular risk factors among patients with head and neck cancer in a clinical cohort 2022
    2022 Intralesional SD-101 in Combination with Pembrolizumab in Anti-PD-1 Treatment-Naïve Head and Neck Squamous Cell Carcinoma: Results from a Multicenter, Phase II Trial.  Clinical Cancer Research.  28:1157-1166. 2022
    2021 An open-label, pilot study of veliparib and lapatinib in patients with metastatic, triple-negative breast cancer.  Breast Cancer Research.  23. 2021
    2021 Pain, Weight Loss, and Quality of Life in a Supportive Care Trial for Patients With Advanced Head and Neck Cancer 2021
    2021 A Phase 1b trial of prexasertib in combination with chemoradiation in patients with locally advanced head and neck squamous cell carcinoma.  Radiotherapy and Oncology.  157:203-209. 2021
    2021 Lipid microsphere bound oxycodone for pain management in patients receiving radiotherapy for head and neck cancer.  Supportive Care in Cancer.  29:263-269. 2021
    2020 Less Toxic Chemotherapy in Locally Advanced Breast Cancer.  Southern Medical Journal.  113:559-563. 2020
    2019 Safety and Efficacy of Durvalumab with or Without Tremelimumab in Patients with PD-L1-Low/Negative Recurrent or Metastatic HNSCC: The Phase 2 CONDOR Randomized Clinical Trial.  JAMA Oncology.  5:195-203. 2019
    2019 Adult cancer pain, version 3.2019.  Journal of the National Comprehensive Cancer Network : JNCCN.  17:977-1007. 2019
    2018 First-line treatment of widely metastatic BRAF-mutated salivary duct carcinoma with combined BRAF and MEK inhibition.  Journal of the National Comprehensive Cancer Network : JNCCN.  16:1166-1170. 2018
    2018 LCCC 1025: a phase II study of everolimus, trastuzumab, and vinorelbine to treat progressive HER2-positive breast cancer brain metastases.  Breast Cancer Research and Treatment.  171:637-648. 2018
    2018 Phase Ib/II, open label, multicenter study of intratumoral SD-101 in combination with pembrolizumab in anti-PD-1 treatment naïve patients with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC).  Annals of Oncology.  29:viii375. 2018
    2017 Implementation and utilization of the molecular tumor board to guide precision medicine..  Oncotarget.  8:57845-57854. 2017
    2017 Antiemesis, version 2.2017 featured updates to the NCCN guidelines.  Journal of the National Comprehensive Cancer Network : JNCCN.  15:883-893. 2017
    2017 Implementation and utilization of the molecular tumor board to guide precision medicine.  Oncotarget.  8:57845-57854. 2017
    2016 A Randomized, Phase II Trial of Cetuximab With or Without PX-866, an Irreversible Oral Phosphatidylinositol 3-Kinase Inhibitor, in Patients With Metastatic Colorectal Carcinoma.  Clinical Colorectal Cancer.  15:337-344.e2. 2016
    2016 Long-term results of a phase I/II trial of the addition of celecoxib to chemoradiotherapy for locally advanced or recurrent squamous cell carcinoma of the head-and-neck.  Journal of radiation oncology.  5:363-369. 2016
    2016 Induction chemotherapy for head and neck cancer: Is there still a role?.  Future Oncology.  12:1595-1608. 2016
    2015 Unique presentation of blastic plasmacytoid dendritic cell neoplasm: A single-center experience and literature review.  Hematological Oncology.  33:206-211. 2015
    2015 Safety and tumor specificity of cetuximab-IRDye800 for surgical navigation in head and neck cancer.  Clinical Cancer Research.  21:3658-3666. 2015
    2015 Phase I dose-escalating trial of Escherichia coli purine nucleoside phosphorylase and fludarabine gene therapy for advanced solid tumors.  Annals of Oncology.  26:1481-1487. 2015
    2014 Assessment of Erlotinib as Adjuvant Chemoprevention in High-Risk Head and Neck Cancer Patients.  Annals of Surgical Oncology.  21:4263-4269. 2014
    2014 A phase II study of medroxyprogesterone acetate in patients with hormone receptor negative metastatic breast cancer: translational breast cancer research consortium trial 007.  Breast Cancer Research and Treatment.  148:99-106. 2014
    2014 African Americans with oropharyngeal carcinoma have significantly poorer outcomes despite similar rates of human papillomavirus-mediated carcinogenesis.  Human Pathology.  45:310-319. 2014
    2013 Phase II trial of bicalutamide in patients with androgen receptor-positive, estrogen receptor-negative metastatic breast cancer.  Clinical Cancer Research.  19:5505-5512. 2013
    2013 Phase 1 study of erlotinib plus radiation therapy in patients with advanced cutaneous squamous cell carcinoma 2013
    2013 Locoregional failure and the risk of distant metastasis after modern radiotherapy for head and neck cancer 2013
    2012 Prognostic significance of thyroid or cricoid cartilage invasion in laryngeal or hypopharyngeal cancer treated with organ preserving strategies.  Radiation Oncology.  7. 2012
    2012 By the pricking of my thumbs, something wicked this way comes*: Sporadic cancers versus eponymous hereditary cancer predisposition syndromes.  Journal of the National Comprehensive Cancer Network : JNCCN.  10:7-13. 2012
    2012 Chemotherapy-resistant metastatic breast cancer.  Current Treatment Options in Oncology.  13:263-275. 2012
    2011 Impact of average weekly dose of radiation during radiotherapy alone or chemoradiotherapy in head and neck cancer 2011
    2011 Long-term follow-up of dose-dense neoadjuvant chemotherapy in patients with stage II/III breast cancer..  Journal of Clinical Oncology.  29:e11048. 2011
    2010 Pilot trial of preoperative (Neoadjuvant) letrozole in combination with bevacizumab in postmenopausal women with newly diagnosed estrogen receptor-or progesterone receptor-positive breast cancer.  Clinical Breast Cancer.  10:275-280. 2010
    2010 Phase I pharmacokinetic and pharmacodynamic study of the oral MAPK/ERK kinase inhibitor PD-0325901 in patients with advanced cancers.  Clinical Cancer Research.  16:1924-1937. 2010
    2009 Factors Associated With Long-Term Dysphagia After Definitive Radiotherapy for Locally Advanced Head-and-Neck Cancer 2009
    2009 Breast cancer: Clinical Practice Guidelines in Oncology™.  Journal of the National Comprehensive Cancer Network : JNCCN.  7:122-192. 2009
    2009 Cancer of the tonsil presenting as central nervous system metastasis: A case report 2009
    2008 NCCN Task Force report: Breast cancer in the older woman.  Journal of the National Comprehensive Cancer Network : JNCCN.  6. 2008
    2008 Locoregionally Advanced Head and Neck Cancer Treated With Primary Radiotherapy: A Comparison of the Addition of Cetuximab or Chemotherapy and the Impact of Protocol Treatment 2008
    2007 The NCCN. Invasive breast cancer: Clinical practice guidelines in oncology™.  Journal of the National Comprehensive Cancer Network : JNCCN.  5:246-312. 2007
    2006 Safety and effectiveness of dose dense neoadjuvant chemotherapy in patients with stage II/III breast cancer..  Journal of Clinical Oncology.  24:10622. 2006
    2006 Genetic/familial high-risk assessment: Breast and ovarian. Clinical Practice Guidelines in Oncology™.  Journal of the National Comprehensive Cancer Network : JNCCN.  4:156-176. 2006
    2005 Breast cancer: Clinical practice guidelines in oncology.  Journal of the National Comprehensive Cancer Network : JNCCN.  3:238-289. 2005
    2004 Preliminary results of Radiation Therapy Oncology Group 97-03: A randomized phase II trial of concurrent radiation and chemotherapy for advanced squamous cell carcinomas of the head and neck.  Journal of Clinical Oncology.  22:2856-2864. 2004
    2004 Improving the effectiveness of adjuvant psychological treatment for women with breast cancer: The feasibility of providing online support 2004
    2003 Docetaxel with concurrent radiotherapy in head and neck cancer..  Seminars in Oncology.  30:89-93. 2003
    2002 Management of a patient with HIV infection-induced anemia and thrombocytopenia who presented with thrombotic thrombocytopenic purpura.  American Journal of Hematology.  69:228-231. 2002
    2000 NCCN Practice Guidelines for Breast Cancer..  Oncology (Williston Park, N.Y.).  14:33-49. 2000
    1999 Update: NCCN practice guidelines for the treatment of breast cancer.  Oncology (Williston Park, N.Y.).  13:41-66. 1999
    1997 Targeted expression of a dominant negative epidermal growth factor receptor in the mammary gland of transgenic mice inhibits pubertal mammary duct development. 1997
    1997 Targeted expression of a dominant negative epidermal growth factor receptor in the mammary gland of transgenic mice inhibits pubertal mammary duct development 1997
    1995 Signal transduction by a CD16/CD7/Jak2 fusion protein.  Journal of Biological Chemistry.  270:18420-18427. 1995
    1994 Human immunodeficiency virus 1 Tat stimulates transcription of the transforming growth factor α gene in an epidermal growth factor-dependent manner.  Molecular Cancer Research.  5:87-93. 1994
    1987 17 beta-estradiol acts directly on the clonal osteoblastic cell line UMR106. 1987

    Research Overview

  • Head and Neck Cancer
    Breast Cancer
    GU cancer
    Sarcoma

    • Principal Investigator On

  • A Phase II Study Evaluating the Efficacy and Tolerability of Everolimus (RAD001) in Combination with Trastuzumab and Vinorelbine in the Treatment of Progressive HER2-Positive Breast Cancer Brain Metastases  awarded by University of North Carolina at Chapel Hill
  • Private Grant  awarded by VIVENTIA BIO, INC.
  • Private Grant  awarded by EXELIXIS, INC.
  • Private Grant  awarded by Genentech
  • Private Grant  awarded by ONCOLYTICS BIOTECH
  • Private Grant  awarded by NOVARTIS PHARMACEUTICALS CORPORATION
  • Private Grant  awarded by ONCOTHYREON, INC.
  • Private Grant  awarded by ONCOTHYREON, INC.
  • Private Grant  awarded by ONCONOVA THERAPEUTICS
  • Private Grant  awarded by ASTRAZENECA PHARMACEUTICALS LP
  • Private Grant  awarded by ASTRAZENECA PHARMACEUTICALS LP
  • Private Grant  awarded by ASTRAZENECA PHARMACEUTICALS LP
  • Private Grant  awarded by DYNAVAX TECHNOLOGIES CORPORATION
  • Private Grant  awarded by ALTOR BIOSCIENCE CORPORATION
  • Private Grant  awarded by BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. ^
  • Private Grant  awarded by MERCK & COMPANY, INC. ^
  • Private Grant  awarded by ASTEX PHARMACEUTICALS
  • Private Grant  awarded by ACERTA PHARMA B.V.
  • Private Grant  awarded by ASTELLAS PHARMA GLOBAL DEVELOPMENT, INC. - NEW
  • Private Grant  awarded by IOVANCE BIOTHERAPEUTICS INC.
  • Private Grant  awarded by Bayer HealthCare
  • Private Grant  awarded by F.Hoffmann-La Roche Ltd.
  • Private Grant  awarded by SYNDAX PHARMACEUTICALS
  • Private Grant  awarded by ASTRAZENECA PHARMACEUTICALS LP
  • Private Grant  awarded by CELGENE CORPORATION
  • Private Grant  awarded by ADURO BIOTECH, INC.
  • Private Grant  awarded by ZYMEWORKS BIOPHARMACEUTICALS
  • Private Grant  awarded by NOVARTIS PHARMACEUTICALS CORPORATION
  • Private Grant  awarded by HOOKIPA BIOTECH
  • Private Grant  awarded by Genentech
  • Private Grant  awarded by REPLIMUNE GROUP INC.
  • Private Grant  awarded by AMGEN, INC.^
  • Private Grant  awarded by ELIOS THERAPEUTICS
  • Private Grant  awarded by IMMUTEP LTD
  • Private Grant  awarded by IDERA PHARMACEUTICALS, INC.
  • Private Grant  awarded by INCYTE CORPORATION
  • Private Grant  awarded by SEAGEN INC
  • UAB 1018/TBCRC 011; Bicalutamide for the Treatment of Androgen Receptor Positive (AR(+)), Estrogen Receptor Negative, Progesterone Receptor Negative (ER(-)/PR(-)), Metastatic Breast Cancer Patients: A Phase II Feasibility Study  awarded by SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH
  • UAB 1428 – A Phase II Randomized Controlled Trial of Genomically Directed Therapy After Preoperative Chemotherapy in Patients with Triple Negative Breast Cancer (HOG Trial)  awarded by HOOSIER CANCER RESEARCH NETWORK

    • Investigator On

  • A Prospective Analysis of Surgery in Patients Presenting with Stage IV Breast Cancer - TBCRC 013 / UAB 0953  awarded by Johns Hopkins University
  • Alliance for Clinical Trials in Oncology Payment Agreement  awarded by MAYO CLINIC
  • Alliance for Clinical Trials in Oncology Payment Agreement  awarded by MAYO CLINIC
  • Biomarkers for Detection of Renal Cell Carcinoma  awarded by American Cancer Society, Inc.
  • ECOG-ACRIN Purchase Service Agreement  awarded by Eastern Cooperative Oncology Group
  • ECOG-ACRIN Purchase Service Agreement  awarded by Eastern Cooperative Oncology Group
  • Imaging Guided Surgery using Fluorescently Labeled Cetuximab  awarded by National Cancer Institute/NIH/DHHS
  • NRG Oncology Member Institution Clinical Trial Fixed Price Subaward Agreement  awarded by NRG ONCOLOGY FOUNDATION
  • Phase 1, Open-Label Study Evaluating the Safety and Pharmacokinetics of Escalating Doses of Cetuximab-IRDye800 as an Optical Imaging Agent to Detect Cancer during Surgical Procedures  awarded by Stanford University
  • Phase I, Open-label Study Evaluating the Safety and Pharmacokinetics of Escalating Doses of Panitumumab-IRDye800 as an Optical Imaging Agent to Detect Head and Neck Cancer During Surgical Procedures  awarded by Stanford University
  • Private Grant  awarded by Genentech
  • Private Grant  awarded by PNP THERAPEUTICS, INC.
  • Private Grant  awarded by BRISTOL MYERS SQUIBB PHARMACEUTICAL COMPANY
  • Private Grant  awarded by NOVARTIS PHARMACEUTICALS CORPORATION
  • Private Grant  awarded by Genentech
  • Private Grant  awarded by SEATTLE GENETICS, INC.
  • Private Grant  awarded by SEATTLE GENETICS, INC.
  • Private Grant  awarded by Genentech
  • Private Grant  awarded by TRACON PHARMACEUTICALS, INC.
  • Private Grant  awarded by OBI PHARMA, INC.
  • Private Grant  awarded by F.Hoffmann-La Roche Ltd.
  • Private Grant  awarded by Sanofi US Services Inc
  • Private Grant  awarded by DYNASPLINTT SYSTEM, INC.
  • Private Grant  awarded by WYETH PHARMACEUTICALS, INC.
  • Private Grant  awarded by F.Hoffmann-La Roche Ltd.
  • Private Grant  awarded by MERRIMACK PHARMACEUTICALS, INC.
  • Private Grant  awarded by NOVARTIS PHARMACEUTICALS CORPORATION
  • Private Grant  awarded by NOVADAQ TECHNOLOGIES, INC.
  • Private Grant  awarded by SYNTA PHARMACEUTICALS
  • Private Grant  awarded by MERRIMACK PHARMACEUTICALS, INC.
  • Private Grant  awarded by INCYTE CORPORATION
  • Private Grant  awarded by Pfizer Inc., U.S. Pharmaceuticals Group
  • Private Grant  awarded by ELI LILLY AND COMPANY
  • Private Grant  awarded by AVEO PHARMACEUTICALS, INC
  • Private Grant  awarded by SEATTLE GENETICS, INC.
  • Private Grant  awarded by JANSSEN RESEARCH & DEVELOPMENT, LLC
  • Private Grant  awarded by Novartis Pharma AG
  • Private Grant  awarded by CELLDEX THERAPEUTICS, INC.
  • Private Grant  awarded by ABBVIE INC
  • Private Grant  awarded by F.Hoffmann-La Roche Ltd.
  • Private Grant  awarded by Pfizer Inc., U.S. Pharmaceuticals Group
  • Private Grant  awarded by INCYTE CORPORATION
  • Private Grant  awarded by NOVARTIS PHARMACEUTICALS CORPORATION
  • Private Grant  awarded by SEATTLE GENETICS, INC.
  • Private Grant  awarded by SELEXYS
  • Private Grant  awarded by CYCLACEL LTD
  • Private Grant  awarded by LICOR, INC.
  • Private Grant  awarded by NOVARTIS PHARMACEUTICALS CORPORATION
  • Private Grant  awarded by TRACON PHARMACEUTICALS, INC.
  • Private Grant  awarded by ELI LILLY AND COMPANY
  • Private Grant  awarded by SUCAMPO PHARMACEUTICALS
  • Private Grant  awarded by Pfizer Inc., U.S. Pharmaceuticals Group
  • Private Grant  awarded by NOVADAQ TECHNOLOGIES, INC.
  • Private Grant  awarded by REXAHN PHARMACEUTICALS, INC.
  • Private Grant  awarded by AMGEN, INC.^
  • Private Grant  awarded by REXAHN PHARMACEUTICALS, INC.
  • Private Grant  awarded by CLOVIS ONCOLOGY
  • Private Grant  awarded by TRACON PHARMACEUTICALS, INC.
  • Private Grant  awarded by CLOVIS ONCOLOGY
  • Private Grant  awarded by ASTRAZENECA AB
  • Private Grant  awarded by Pfizer Inc., U.S. Pharmaceuticals Group
  • Private Grant  awarded by IMAGINAB^
  • Private Grant  awarded by SEATTLE GENETICS, INC.
  • Private Grant  awarded by ASTEX PHARMACEUTICALS
  • Private Grant  awarded by ELI LILLY AND COMPANY
  • Private Grant  awarded by PUMA BIOTECHNOLOGY, INC.
  • Private Grant  awarded by ASTRAZENECA PHARMACEUTICALS LP
  • Private Grant  awarded by ELI LILLY AND COMPANY
  • Private Grant  awarded by TRACON PHARMACEUTICALS, INC.
  • Private Grant  awarded by NOVARTIS PHARMACEUTICALS CORPORATION
  • Private Grant  awarded by MERCK SHARP & DOHME CORP
  • Private Grant  awarded by SEATTLE GENETICS, INC.
  • Private Grant  awarded by SEATTLE GENETICS, INC.
  • Private Grant  awarded by STRATA ONCOLOGY
  • Private Grant  awarded by ASTRAZENECA PHARMACEUTICALS LP
  • Private Grant  awarded by TACTILE MEDICAL
  • Private Grant  awarded by MUREVA PHOTOTHERAPY INC
  • Private Grant  awarded by JOUNCE THERAPEUTICS, INC
  • Private Grant  awarded by STRATA ONCOLOGY
  • Private Grant  awarded by CELGENE CORPORATION
  • Private Grant  awarded by EMD SERONO
  • Private Grant  awarded by GREENWICH LIFESCIENCES, INC.
  • Private Grant  awarded by BRIACELL THERAPEUTICS CORP.
  • Private Grant  awarded by ASTELLAS PHARMA GLOBAL DEVELOPMENT, INC. - NEW
  • Private Grant  awarded by ANAVEON AG
  • Reduction of Tumor-Positive Margins in Oncology Surgery  awarded by National Cancer Institute/NIH/DHHS
  • SWOG Purchase Services Agreement  awarded by Oregon Health & Science University
  • Southwest Oncology Group Clinical Trials Initiative Purchase Service Agreement  awarded by SOUTHWEST ONCOLOGY GROUP
  • Southwest Oncology Group Purchase Service Agreement  awarded by SOUTHWEST ONCOLOGY GROUP
  • TBCRC 026/UAB 1367: A Phase 2 Clinical Trial Assessing the Correlation of Early Changes in Standardized Uptake Value (SUV) on Positron Emission Tomography (PET) with Pathological Complete Response (pCR) to Pertuzumab and Trastuzumab in Patients with Primary Operable HER2-Positive Breast Cancer (ML28190)  awarded by Johns Hopkins University
  • TBCRC 036 (UAB 1366): Defining the HER2 Positive (+) Breast Cancer Kinome Response to Trastuzumab, Pertuzumab, Combination Trastuzumab + Pertuzumab, or Combination Trastuzumab + Lapatinib  awarded by Lineberger Comprehensive Care Center
  • TBCRC 042 UAB 1905: A Randomized, Phase II, Window-of-Opportunity Trial of Ruxolitinib in Patients with High Risk and Premalignant Breast Conditions  awarded by Johns Hopkins University
  • TBCRC030 - A Randomized Phase II Study of Preoperative Cisplatin versus Paclitaxel in Patients with Triple Negative Breast Cancer: Evaluating the Homologous Recombination Deficiency (HRD) Biomarker  awarded by Johns Hopkins University
  • UAB 1018/TBCRC 011; Bicalutamide for the Treatment of Androgen Receptor Positive (AR(+), Estrogen Receptor Negative, Progesterone Receptor Negative (ER(-)/PR(-), Metastatic Breast Cancer Patients: A Phase II Feasibility Study  awarded by Johns Hopkins University
  • UAB 1019/TBCRC 015: Investigation of Genetic Determinants of Capecitabine Toxicity  awarded by Johns Hopkins University
  • UAB 1033/TBCRC 018: A Phase II Study of the PARP Inhibitor, INIPARIB (BSI-201) in Combination with Chemotherapy to Treat Triple Negative Breast Cancer Brain Metastasis  awarded by Johns Hopkins University
  • UAB 1174: Investigation of Serial Studies to Predict your Therapeutic Response with Imaging and Molecular Analysis 2  awarded by QUANTUM LEAP HEALTH CARE
  • UAB 1174: Investigation of Serial Studies to Predict your Therapeutic Response with Imaging and Molecular Analysis 2  awarded by QUANTUM LEAP HEALTH CARE
  • UAB 1326: A Phase II Study of Neratinib Alone and in Combination with Fulvestrant in Metastatic HER2 Non-Amplified but HER2 Mutant Breast Cancer  awarded by Washington University
  • UAB 1764:The Targeted Agent and Profiling Utilization Registry (TAPUR) Study  awarded by American Society of Clinical Oncology
  • UAB NRG Oncology Master Institution Purchased Service Agreement  awarded by NRG ONCOLOGY FOUNDATION
  • UAB NRG Oncology Member Institution Purchased Service Agreement  awarded by NRG ONCOLOGY FOUNDATION
  • UAB NRG Oncology Member Institution Purchased Service Agreement  awarded by NRG ONCOLOGY FOUNDATION
  • XUAB 2167 - A Phase II Circulating Tumor DNA Enriched, Gnomically Directed Post-Neoadjuvant Trial for Patients with Residual Triple Negative Breast Cancer (PERSEVERE): HCRN BRE18-334  awarded by HOOSIER CANCER RESEARCH NETWORK
  • [18F] Fluoroestradiol (FES) PET as a Predictive Measure for Endocrine Therapy in Women with Newly Diagnosed Metastatic Breast Cancer (R20-146)  awarded by ECOG-ACRIN CANCER RESEARCH GROUP

    • Education And Training

  • UAB Hospital, Internship
  • UAB Hospital, Residency
  • UAB Hospital, Postdoctoral Fellowship
  • Doctor of Medicine, University of North Carolina System : Chapel Hill 1987

    • Full Name

  • Lisle Nabell